Kazia Therapeutics Limited
KZIA · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | – | $22 | $2,481 | $0 |
| % Growth | – | -99.1% | 49,619,800% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $22 | $2,481 | $0 |
| % Margin | – | 100% | 100% | 100% |
| R&D Expenses | – | $4,282 | $13,052 | $4,328 |
| G&A Expenses | – | $5,109 | $9,007 | $4,556 |
| SG&A Expenses | – | $5,109 | $9,007 | $4,556 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $9,391 | $22,060 | $8,883 |
| Operating Income | – | -$9,368 | -$19,579 | -$8,883 |
| % Margin | – | -42,029.5% | -789.1% | -177,668,060% |
| Other Income/Exp. Net | – | -$1,221 | $1,489 | -$76 |
| Pre-Tax Income | – | -$10,589 | -$18,090 | -$8,959 |
| Tax Expense | – | -$136 | -$135 | -$136 |
| Net Income | – | -$10,454 | -$17,954 | -$8,824 |
| % Margin | – | -46,899.1% | -723.7% | -176,470,260% |
| EPS | – | -6.15 | -31.2 | -18.4 |
| % Growth | – | 80.3% | -69.6% | – |
| EPS Diluted | – | -6.15 | -31.2 | -18.4 |
| Weighted Avg Shares Out | – | 850 | 575 | 480 |
| Weighted Avg Shares Out Dil | – | 850 | 575 | 480 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $14 | $6 | $6 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $935 | $934 | $935 |
| EBITDA | – | -$8,434 | -$18,644 | -$7,949 |
| % Margin | – | -37,836.1% | -751.5% | -158,973,960% |